OncoMatch/Clinical Trials/NCT07753343
Identification and Description of Patients With High-risk Non Metastatic RCC
Is NCT07753343 recruiting? Yes, currently enrolling (Sep 2026).
Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage LOCAL RCC, HIGH-RISK LOCALLY ADVANCED RCC
Excluded: Stage METASTATIC DISEASE
local RCC or high-risk locally advanced RCC; Patients with metastatic disease at inclusion [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07753343 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage LOCAL RCC or HIGH-RISK LOCALLY ADVANCED RCC is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages